Clinical Infectious Diseases (CID) – Volume 62 Issue 1 January 1, 2016

Clinical Infectious Diseases (CID)
Volume 62 Issue 1 January 1, 2016

The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field
Johan van Griensven, Anja De Weiggheleire, Alexandre Delamou, Peter G. Smith, Tansy Edwards, Philippe Vandekerckhove, Elhadj Ibrahima Bah, Robert Colebunders, Isola Herve, Catherine Lazaygues, Nyankoye Haba, and Lutgarde Lynen
Clin Infect Dis. (2016) 62 (1): 69-74 doi:10.1093/cid/civ680
Clinical evaluation of convalescent plasma (CP) as Ebola treatment in the current outbreak was prioritized by the World Health Organization. Although no efficacy data are available, current field experience supports the safety, acceptability, and feasibility of CP as Ebola treatment.


Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection
Murli U. Purswani, Brad Karalius, Tzy-Jyun Yao, D. Scott Schmid, Sandra K. Burchett, George K. Siberry, Kunjal Patel, Russell B. Van Dyke, and Ram Yogev for the Pediatric HIV/AIDS Cohort Study (PHACS)
Clin Infect Dis. (2016) 62 (1): 106-114 doi:10.1093/cid/civ734
Long-term persistence of varicella antibodies was strongly associated with administration of 2 varicella vaccines in perinatally human immunodeficiency virus–infected children. Vaccination after ≥3 months of combination antiretroviral therapy and duration of such therapy were also determinants of vaccine immunogenicity